EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Acute Kidney Injury Associated with Novel Anticancer Therapies

Sabine Karam iD, Ala Ali iD, Winston Fung iD, Prashant Mehta iD, Sanjeev Nair iD, Urmila Anandh iD

Kidney360 · 2025

DOI: 10.34067/kid.0000000749 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney360, 2025. Verfasst von Sabine Karam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minneapolis. Hauptthemen laut MEDLINE: Acute Kidney Injury, Immune Checkpoint Inhibitors, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of cancer survival has been positively affected by the introduction and dissemination of immunotherapy with the wide usage of immune checkpoint inhibitors and chimeric antigen receptors cell therapies. The success of these novel therapies can, however, be limited to a certain extent by systemic inflammatory toxicities affecting, directly or indirectly, the kidney. In the case of immune checkpoint inhibitors, severe acute interstitial nephritis is the main adverse event and can lead to permanent discontinuation of the therapy. In turn, chimeric antigen receptor cell therapy can cause cytokine release syndrome and immune effector cell-associated hemophagocytic lympho-histiocytosis, with kidney damage through various mechanisms, and be life threatening. Prompt diagnosis and management of these entities is essential to preserve kidney function and ensure the best possible kidney and overall outcomes to patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryImmune Checkpoint InhibitorsNeoplasmsImmunotherapyImmunotherapy, AdoptiveHumansCytokine Release SyndromeNephritis, InterstitialReceptors, Chimeric Antigen

Stichwörter der Autor:innen

AKIclinical nephrologydrug nephrotoxicity

Substanzen

Immune Checkpoint InhibitorsReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minneapolis.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
  • Nephrology and Renal Transplantation Center, The Medical City, Baghdad, Iraq.
  • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Hematology, Medical Oncology and Bone Marrow Transplantation, Amrita Institute of Medical Sciences and Research Centre, Faridabad, India.
  • Department of Nephrology, Madras Medical Mission, Chennai, India.

ORCID-Profile: Sabine Karam, Ala Ali, Winston Fung, Prashant Mehta, Sanjeev Nair, Urmila Anandh

Zitieren

APA

Karam, S., Ali, A., Fung, W., Mehta, P., Nair, S., & Anandh, U. (2025). Acute Kidney Injury Associated with Novel Anticancer Therapies. Kidney360. https://doi.org/10.34067/kid.0000000749

Vancouver

Karam S, Ali A, Fung W, Mehta P, Nair S, Anandh U. Acute Kidney Injury Associated with Novel Anticancer Therapies. Kidney360. 2025. doi:10.34067/kid.0000000749

BibTeX
@article{Karam2025,
  author = {Karam, Sabine and Ali, Ala and Fung, Winston and Mehta, Prashant and Nair, Sanjeev and Anandh, Urmila},
  title = {Acute Kidney Injury Associated with Novel Anticancer Therapies},
  journal = {Kidney360},
  year = {2025},
  doi = {10.34067/kid.0000000749}
}
Kostenlos starten →